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TO THE EDITOR
Epidermolysis bullosa simplex (EBS) is a
group of hereditary mechanobullous
disorders. Dominant negative muta-
tions in the keratin 5 (KRT5, 12q13)
and keratin 14 (KRT14, 17q12–q21)
genes have been identified in most
EBS patients (Fine et al., 1991; Irvine
and McLean, 1999). In the most severe
EBS subtype, Dowling-Meara (EBS-DM),
a generalized herpetiform skin blister-
ing is present. In contrast, the Ko¨bner
form (EBS-K) shows a milder, general-
ized blistering, whereas blistering in
EBS Weber-Cockayne (EBS-WC) typically
involves the palms and soles (Sorensen
et al., 2003).
Molecular diagnosis of keratin dis-
orders are complicated by the presence
of dysfunctional pseudogenes (Smith,
2003). KRT14 has a truncated and a
full-length inactive pseudogene
(Savtchenko et al., 1988). To avoid
KRT14 pseudogene amplification, addi-
tional methods have been established,
such as long-range PCR and cDNA
analyses (Wood et al., 2003), which
are cost- and time-consuming methods.
The most commonly applied genomic
restriction digestion combined with
PCR (Hut et al., 2000; Schuilenga-Hut
et al., 2003) is often unreliable, because
trace amounts of undigested sequences
can be re-amplified, whereas overdi-
gestion may result in noncompleted
amplification due to star activity of the
enzymes.
The variable success of previously
published methods led us to develop a
new, single-step, allele-specific PCR to
avoid sequence contamination from
KRT14 pseudogenes. The KRT5 and
KRT14 mutations carry useful informa-
tion about genotype–phenotype corre-
lations.
Evaluation of the new KRT14 muta-
tion strategy: the new approach for
KRT14 analysis proved to be a simply
mutation analysis strategy in EBS that
successfully excluded pseudogene se-
quence contamination.
Two EBS- DM, one EBS-K, and six
EBS-WC families were referred to us by
DEBRA Hungary. They were unrelated
and nonconsanguineous (Table 1).
Study protocol, patient information
sheet and patient consent forms were
reviewed and approved by IRB (SE
TUKEB 157-1997/98).
Genomic DNA was isolated from
200ml peripheral blood by NucleoSpin
DNA kit (Macherey Nagel GmbH,
Du¨ren, Germany).
Exons 1–9 of KRT5 (AF274874.1,
National Center for Biotechnology In-
formation) and exons 1–8 of KRT14
(J00124, National Center for Biotech-
nology Information) were amplified.
PCR was set up with 2 ImmoMix
(Bioline, London, UK). Amplification
conditions: hot-start initiation, 951C/
10 minutes; 40 cycles, 951C/45 sec-
onds; 30 seconds at optimal annealing
temperature, 57–641C, 721C/30 sec-
onds; final elongation, 721C/5 minutes.
Annealing temperatures for KRT5 pri-
mers were described by Stephens et al.
(1997) and Schuilenga-Hut et al. (2003).
Considering the highly polymorphic
nature of KRT14, we studied possible
annealing sites for allele-specific pri-
mers, excluding sites with known in-
tronic polymorphisms. Primers for
KRT14 were designed by careful com-
parison of the highly homologous full
KRT14 pseudogene (NG_002781.1,
National Center for Biotechnology In-
formation) and the functional KRT14
(Table S1). Priming sites were chosen to
bare nucleotide differences.
Annealing sites were researched for
intronic single nucleotide polymorph-
isms in genomic databases (Pubmed:
GeneBank, Nucleotid/BLAST and single
nucleotide polymorphism databases
Altchul et al., (1997) (www.pubmed.
com)), USSC Genome Bioinformatic
database and BLAT (www.genome.
ucsc.edu), ABi/CELERA single nucleo-
tide polymorphism browser software
(Applied Biosystems, Foster City, CA),
single nucleotide polymorphism BLAST
tool (www.snp.ims.u-tokyo.ac.jp). Primer
specificity was reproofed with Primer3
(Rozen and Skaletsky, 2000) and Vec-
torNTI (Invitrogen, Carlsbad, CA), anneal-
ing temperatures were determined by in
silico predicament and confirmed by
routine PCR runs.
Amplicons generated with the newly
designed primers were submitted to
direct sequencing. Analysis by the
restriction digestion method was also
carried out in comparison. No pseudo-
gene sequence contamination was
detected by using the newly designed
primers.
Prescreening was routinely carried
out with conformation-sensitive gel
electrophoresis and heteroduplex
analysis described earlier (Csiko´s
et al., 2004, 2005). Exon 1 of both
genes were not prescreened, but sub-
mitted to direct sequencing in all cases.
Mutations and polymorphisms were
reconfirmed by restriction digestion.
If no restriction site was available,
resequencing was repeatedly carried
out. Allele frequencies were deter-
mined in the Hungarian population by
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Abbreviations: EBS, epidermolysis bullosa simplex; EBS-DM, epidermolysis bullosa simplex Dowling-
Meara; EBS-K, epidermolysis bullosa simplex Ko¨bner; EBS-WC, epidermolysis bullosa simplex Weber-
Cockayne; KRT14, keratin 14 gene; KRT5, keratin 5 gene
screening 100 non-EBS control DNA
samples (200 chromosomes; Table 1).
We identified KRT14 mutations in
four out of nine EBS families. The other
five EBS pedigrees carried KRT5 muta-
tions. Seven out of nine mutations share
codons with those described previously
in EBS (Table 1). All the identified
mutations occur in the conserved co-
dons of KRT5 or KRT14: none of the
200 chromosomes/100 studied controls
carried the mutations.
KRT5 mutations and genotype–phe-
notype correlations: in family 2 (EBS-
WC) the heterozygous c.547A4G,
p.I183V was present. P.I183F, a differ-
ent mutation in the same codon, had
been previously described (Pfendner
et al., 2003) in EBS-DM. Because of
its smaller side chain, valin in P.I183V
might cause less intraproteinic stress
and steric distortion than phenylalanine
in p.I183F, and this might explain the
milder phenotype in our case.
The affected members in family 3
(EBS-WC) carried the heterozygous
mutation c.570G4C, p.E190D in exon
1. The previously reported p.E190K also
induced a EBS-WC phenotype (Mu¨ller
et al., 2006).
Family 5 (EBS-WC): in exon 5 a
heterozygous substitution c.991C4G is
present which results in p.R331G. Two
other EBS-WC mutations at this codon
(p.R331C, p.R331H) had been pre-
viously reported (Rugg et al., 1993;
Mu¨ller et al., 2006).
Families 1 (EBS-WC) and 4 (EBS-K)
carried the known p.E170K and
p.Q191P, respectively (Yasukawa
et al., 2002; Mu¨ller et al., 2006), with
the previously observed phenotype.
KRT14 mutations and genotype–phe-
notype correlations: family 6 (EBS-WC)
presented with the c.407T4A,
p.L136Q mutation. Polarity change
could lead to defected filament interac-
tions and could be therefore pathogenic.
In EBS-DM family 8, the affected
proband carried the heterozygous
c.1231G4A, p.E411K in exon 6. As
the mutation was absent from the
parents, a de novo mutation or gonadal
mosaicism was probable. Known muta-
tions of KRT14 at codon 411, p.E411X,
Glu411del (c.1231_1233delGAG),
have been associated with EBS-DM
(Gu et al., 2002; Mu¨ller et al., 2006).
All the affected members of family 9
(EBS-DM) were found to be heterozy-
gous for a new T4A transversion
c.1235T4A (exon 6), which resulted
in the Ile4124Asn substitution
(p.I412N).
Family 7 (EBS-WC) carried the re-
current mutation p.R388C (Chen et al.,
1995; Rugg et al., 2007) with the
previously published phenotype.
All the participating family members
gave their written consent to mutation
analysis. Protocol, patient information
sheet and patient consent forms were
reviewed and approved by IRB’s of the
Semmelweis University and the
Regional Ethincal Committee Central-
Hungary (SE TUKEB 157-14 1997/98).
This study was conducted according to
the Declaration of Helsinki principles.
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Table 1. KRT5 and KRT14 mutations and polymorphisms in EBS families
Pedigrees
Clinical
phenotype
Keratin
gene Exon
Affected
keratin
domain cDNA
Triplet
change
Mutation
(amino-acid substitution) Validation Inheritance
Allele
frequency
1 EBS-WC KRT5 1 1A c.508G4A GAG-AAG p.E170K (Glu-Lys) Sequencing Paternal —
2 EBS-WC KRT5 1 1A c.547A4G ATC-GTC p.I183V (Ile-Val) Sequencing Paternal —
KRT 5 1 1A c.382G4C GGT-CGT p.G128R (Gly-Arg) Sequencing Paternal 0.59
3 EBS-WC KRT5 2 1A c.570G4C GAG-GAC p.E190D (Glu-Asp) TseI. (–) Paternal —
KRT5 1 1B c.513G4A CAG-GAA p.Q171Q (Gln-Gln) Sequencing Maternal 0.54
4 EBS-K KRT5 2 1A c.572A4C CAG-CCG p.Q191P (Gln-Pro) TseI. (–) Paternal —
5 EBS-WC KRT5 5 L1-2 c.991C4G CGC-GGC p.R331G (Arg-Gly) AciI. (–) Paternal —
KRT5 1 Head c.156C4A GCC-GCA p.A52A (Ala-Ala) Sequencing Paternal 0.34
6 EBS-WC KRT14 1 1A c.407T4A CTG-CAG p.L136Q (Leu-Gln) DdeI. (+) Maternal —
7 EBS-WC KRT14 6 2B c.1162C4T CGC-TGC p.R388C (Arg-Cys) AciI. (–) Paternal —
8 EBS-DM KRT14 6 2B c.1231G4A GAG-AAG p.E411K (Glu-Lys) MboII. (+) De Novo —
KRT5 1 1B c.630T4C ACC-ACA p.T210T (Thr-Thr) Sequencing Maternal 0.66
9 EBS-DM KRT14 6 2B c.1235T4A ATC-AAC p.I412N (Ile-Asn) Sau3AI. (+) Paternal —
KRT14 1 Head c.369T4C AAT-AAC p.N123N (Asn-Asn) Sequencing Maternal 0.38
EBS-DM, epidermolysis bullosa simplex Dowling-Meara; EBS-K, epidermolysis bullosa simplex Ko¨bner; EBS-WC, epidermolysis bullosa simplex
Weber-Cockayne.
Novel mutations are indicated in bold, polymorphisms in italic letters; () mutation abolishes the restriction site; (+) mutation generates the restriction site.
Allele frequencies are calculated upon studies in 100 unrelated control individuals (200 chromosomes).
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TO THE EDITOR
In the treatment of psoriasis, fumaric
acid esters show good clinical efficacy
combined with a favorable safety pro-
file (Mrowietz et al., 1999).
Fumaderm, registered in Germany,
consists of dimethylfumarate (DMF) and
three salts of monoethylfumarate (MEF),
and it has been shown that only DMF is
required for clinical effect (Nieboer
et al., 1990). It is not yet clear whether
DMF itself represents the active com-
pound in vivo because only its hydro-
lysis product monomethylfumarate
(MMF) could be detected in the plasma
of healthy humans after oral intake
(Litjens et al., 2004a).
DMF exerts pharmacodynamic effects
in low concentrations in vitro but could
not be detected in vivo. In contrast, MMF
showed in vitro effects only at concen-
Abbreviations: DMF, dimethylfumarate; GS-DMS, S-(1,2-dimethoxycarbonylethyl)glutathione;
GSH, glutathione; MEF, monoethylfumarate; MMF, monomethylfumarate; NAC-DMS, N-acetyl-S-(1,2-
dimethoxycarbonylethyl)cysteine; NAC-MES, mixture of N-acetyl-S-(1-carboxy-2-ethoxycarbonylethyl)-
cysteine and N-acetyl-S-(2-carboxy-1-ethoxycarbonylethyl)cysteine; NAC-MMS, mixture of N-acetyl-S-
(1-carboxy-2-methoxycarbonylethyl)cysteine and N-acetyl-S-(2-carboxy-1-methoxycarbonylethyl)-cysteine
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